Updated

Beauty giant L'Oreal's CEO said on October 22 that the use of GLP-1 weight loss drugs is "a very important phenomenon" for the company, indicating the pharmaceutical trend is measurably affecting consumer demand for beauty and skin care products. The disclosure reflects broader economic impacts as weight loss medications like Ozempic and similar GLP-1 receptor agonists gain widespread adoption, with companies in sectors from cosmetics to fashion adjusting their business strategies in response to shifting consumer behaviour and body image trends.